8 results about "Yeast gene" patented technology

A genetically modified yeast cell, wherein the yeast cell comprises a genetic modification comprising overexpression of yeast gene encoding porphobilinogen deaminase (HEM3), the HEM3 gene having at least 80% identity with SEQ ID No. 7. The genome of the modified yeast cell further comprises one or more genetic modifications in one or more genes selected from: genes coding for heme-dependent repressor of hypoxic genes (ROX1), genes coding for heme oxygenase (HMX1), genes coding for a receptor for vacuolar proteases (VPS10), and genes coding for vacuolar proteinase (PEP4), the one or more genetic modifications being such that expression of a polypeptide from such a gene is reduced or disrupted or the polypeptide expressed is non-functional.

The invention relates to a yeast gene modified cell containing GDP-fucose synthase polypeptide, which can be applied to synthesis of human milk oligosaccharide, and belongs to the technical field of gene engineering. According to the technical scheme, the yeast gene modified cell contains a heterologous nucleic acid sequence of a GDP-fucose synthase active polypeptide. The synthetase active polypeptide is obtained by modifying at least one site of the 20th site to the 29th site, the 40th site to the 53th site, the 75th site to the 81st site, the 95th site, the 148th site to the 158th site, the 193th site, the 215th site, the 219th site to the 21st site, the 227th site to the 232 site, the 239th site to the 241st site, the 259th site to the 264th site, the 301st site to the 302 site, the 306th site and the 310th site to the 316th site of an amino acid sequence shown in SEQ ID NO: 1. Compared with an original strain, the yeast gene modified cell has higher activity of synthesizing fucosyllactose, and a safe and feasible technical scheme is provided for industrial production of fucosyllactose.

Lipid production control factors in yeasts are provided. A yeast 115694 gene, a yeast 4888 gene, and a yeast 45559 gene are provided as lipid production control factors.

The invention discloses kluyveromyces marxianus genetically engineered bacteria and application thereof, and belongs to the technical field of bioengineering. The invention discloses a kluyveromyces marxianus genetically engineered bacterium. The kluyveromyces marxianus genetically engineered bacterium is prepared by the following steps: firstly, screening to obtain a kluyveromyces marxianus strain with high ergosterol yield; on the basis, inducing and separating a MATa haploid strain; then, through the introduction of heterologous DHCR24 and DWF5 genes, the weakening of a competitive pathway gene ERG6, the improvement of the metabolic flux of a squalene pathway in a sterol synthesis process, the compartment engineering of a peroxisome region of a mevalonic acid pathway, the knockout of an hypoxia inhibition transcription factor ROX1, the improvement of cofactor supply, the optimization of a yeast lipid pathway and other metabolic engineering optimization reconstructions, the expression of the yeast lipid pathway is improved; and an engineering strain with high cholesterol yield is constructed and obtained. Through fed-batch fermentation, efficient and stable synthesis of cholesterol is achieved, the yield reaches 7.64 g / L, and a foundation is laid for biological manufacturing of cholesterol.

This invention discloses a fully humanized N-glycosylated yeast strain and its applications. The modification of the yeast strain in this invention includes the knockout of basal N-glycosylation, the construction of a humanized N-glycosylation pathway, the integration of genes related to heparin precursor synthesis, and the integration of genes for heparin-modifying enzymes. The N-glycosylated Pichia pastoris platform strain described in this invention represents the first time that full humanization has been achieved, with its N-glycosyl group including fucosylate. When expressing animal-derived heparin-modifying enzymes, the fully humanized Pichia pastoris platform strain of this invention exhibits increased enzyme activity, thereby increasing the sulfate groups in the heparin glycan chains, thus enhancing the biological activity of heparin.

Lipid production control factors in yeasts are provided. A yeast 115694 gene, a yeast 4888 gene, and a yeast 45559 gene are provided as lipid production control factors.

This invention discloses a genetically engineered strain of *Kluyveromyces martensii* and its applications, belonging to the field of bioengineering technology. The invention discloses a genetically engineered *Kluyveromyces martensii* strain, firstly obtained through screening a strain that produces high levels of ergosterol; based on this, it induces and isolates... Eye A haploid strain was constructed and then metabolically optimized through the introduction of heterologous DHCR24 and DWF5 genes, weakening of the competitive pathway gene ERG6, increasing the metabolic flux of the post-squalene pathway during sterol synthesis, peroxisome compartmentalization engineering of the mevalonate pathway, knockout of the hypoxia-inhibiting transcription factor ROX1, improved cofactor supply, and optimization of the yeast lipid pathway, resulting in a high-cholesterol-producing engineered strain. Through fed-batch fermentation, efficient and stable cholesterol synthesis was achieved, with a yield of 7.64 g / L, laying the foundation for cholesterol biomanufacturing.

The application discloses a recombinant Pichia pastoris genetic engineering bacterium with high yield of lactoferrin, and simultaneously satisfies the following three modifications: overexpression of a bovine lactoferrin expression gene, mutation of an alpha mating factor signal peptide at position E86 to F, and overexpression of a PDI molecular chaperone gene. The application also discloses a construction method of the recombinant Pichia pastoris genetic engineering bacterium, and application of the recombinant Pichia pastoris genetic engineering bacterium in production of bovine lactoferrin. The 5L fermenter test result of the bacterium strain shows that the yield of exogenous protein is significantly improved, and is increased from 10.04 mg / L in a flask fermentation to 95.78 mg / L, nearly 10 times. The application is based on the Pichia pastoris system and is not related to complex culture condition change, and is low in cost and easy to enlarge. The method is not only suitable for production of bovine lactoferrin, but also provides a new modification idea for high-efficiency expression of other heterologous proteins in the yeast system.